Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Fineline Cube Jul 10, 2026
Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Fineline Cube Jul 10, 2026
Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Fineline Cube Jul 10, 2026
Company Drug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Fineline Cube Jul 10, 2026
Company Deals Policy / Regulatory

Sinopharm Expands Partnership with Guizhou Government to Boost Health Industry

Fineline Cube Jun 26, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strengthened partnership with the...

Company Deals

Coherent Biopharma and C-Ray Therapeutics Partner to Advance Peptide-Drug Conjugate Development

Fineline Cube Jun 26, 2023

China-based Coherent Biopharma and C-Ray Therapeutics have announced a strategic partnership to delve into the...

Company Drug

CANbridge Pharmaceuticals Reports Positive Phase Ib Results for Omoprubart in PNH Treatment

Fineline Cube Jun 26, 2023

China-based rare disease firm CANbridge Pharmaceuticals Inc., (HKG: 1228) has published the preliminary results of...

Company Medical Device

Sino Medical Sciences Technology Secures FDA Thailand Approval for NC Rockstar Balloon Catheter

Fineline Cube Jun 26, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced that it has received market...

Company Drug

Haisco Pharmaceutical’s HSK31679 Receives Clinical Trial Approval for NASH Treatment

Fineline Cube Jun 26, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its in-house developed Category...

Company Drug

NMPA Approves XZenith Biopharm’s Anaprazole for Duodenal Ulcer Treatment

Fineline Cube Jun 26, 2023

The National Medical Product Administration (NMPA) has granted marketing approval for anaprazole, a proton pump...

Company Drug

Sichuan Kelun’s SKB264 Earns Breakthrough Therapy Designation for Breast Cancer Treatment

Fineline Cube Jun 26, 2023

The Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Kelun Pharmaceutical Co.,...

Company Drug

Brii Biosciences Partners Present Chronic Hepatitis B Clinical Results at EASL 2023

Fineline Cube Jun 26, 2023

China’s Brii Biosciences (HKG: 2137) announced that its strategic partners, Vir Biotechnology Inc., (NASDAQ: VIR)...

Company Deals

Shionogi’s Acquisition of Qpex Impacts Brii Biosciences’ Rights to Anti-infective Drugs

Fineline Cube Jun 26, 2023

Japan’s Shionogi & Co., Ltd (TYO: 4507) announced on June 26, 2023, its planned acquisition...

Company Deals Drug

Innovent Biologics and RemeGen Partner on Clinical Study for PD-1 Inhibitor and ADC Drugs

Fineline Cube Jun 26, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has entered into a clinical study and supply cooperation...

Company Drug

Sino-Cuban JV Biotech Pharmaceutical Receives NMPA Approval for Nimotuzumab in Pancreatic Cancer

Fineline Cube Jun 25, 2023

Sino-Cuban joint venture (JV) Biotech Pharmaceutical Limited (BPL) announced last week that it has received...

Company Drug

Sarepta Therapeutics’ Elevidys Receives FDA Accelerated Approval for Duchenne Muscular Dystrophy

Fineline Cube Jun 25, 2023

US-based Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has announced that the U.S. Food and Drug Administration...

Company Drug

S-Evans Biosciences Receives NMPA Tacit Approval for Stem Cell Therapy in ARDS

Fineline Cube Jun 25, 2023

S-Evans Biosciences, a stem cell specialist based in Hangzhou, has obtained tacit clinical trial approval...

Company Deals

Kite Pharma’s Yescarta Marketing Rights Transferred to Gilead Sciences K.K. in Japan

Fineline Cube Jun 25, 2023

US immunotherapy specialist Kite Pharma, Inc. has announced that the Marketing Authorization for Yescarta (axicabtagene...

Company Drug

Hopstem Biotechnology’s hNPC01 Receives Tacit Approval for Stroke Sequelae Treatment from CDE

Fineline Cube Jun 25, 2023

Hopstem Biotechnology Co., Ltd, a neural stem cell specialist founded by neuroscientists and stem-cell biologists...

Company Deals

Edding Pharma Aims for Fifth IPO Attempt on Hong Kong Stock Exchange

Fineline Cube Jun 25, 2023

China-based Edding Pharma is gearing up for its fifth attempt to hold an initial public...

Drug Policy / Regulatory

CDE Releases Guidelines for Clinical Trials of Stem Cell Therapies and Derived Products

Fineline Cube Jun 25, 2023

The Center for Drug Evaluation (CDE) has released a set of “Guidelines for Clinical Trial...

Company Drug

Sciwind Biosciences Leads China’s Anti-Obesity Drug Market with GLP-1 Analog Ecnoglutide

Fineline Cube Jun 25, 2023

Sino-US biotech Sciwind Biosciences Co., Ltd has positioned itself as a frontrunner in China’s race...

Drug Policy / Regulatory

CDE Releases Draft Guidelines for Antibody Drug Conjugate Research and Evaluation

Fineline Cube Jun 25, 2023

The Center for Drug Evaluation (CDE) has released a draft set of “Guiding Principles for...

Company Deals

Aureka Biotechnologies Secures $10 Million in Seed Funding for AI-Driven Biotechnology

Fineline Cube Jun 25, 2023

Aureka Biotechnologies Inc., a California-based artificial intelligence (AI)-empowered biotech company, has successfully raised USD 10...

Posts pagination

1 … 538 539 540 … 693

Recent updates

  • Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise
  • Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics
  • Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
  • Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma
  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Company Drug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.